Topical emollient therapy in the management of severe acute malnutrition in children under two: A randomized controlled clinical trial in Bangladesh.


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
Jun 2020
Historique:
entrez: 9 6 2020
pubmed: 9 6 2020
medline: 5 3 2021
Statut: ppublish

Résumé

Topical emollient therapy can improve neonatal health and growth and potentially provides an additional avenue for augmenting the provision of nutrition to children with severe acute malnutrition (SAM). We hypothesised that topical treatment of hospitalised children with SAM using sunflower seed oil (SSO), in addition to standard-of-care for SAM, would improve skin barrier function and weight gain, reduce risk of infection, and accelerate clinical recovery. We conducted a randomised, two-arm, controlled, unblinded clinical trial in 212 subjects aged 2 to 24 months who were admitted for care of SAM at the 'Dhaka Hospital' of icddr,b during January 2016 to November 2017. Enrollment was age-stratified into 2 to <6 months and 6 to 24 months age groups in a 1:2 ratio. All children received SAM standard-of-care, and the SSO group was also treated with 3 g of SSO per kg body weight three times daily for 10 days. Primary outcome was rate of weight gain over the 10-day study period. Secondary endpoints included rate of nosocomial infection, time to recovery from acute illness, skin condition score, rate of transepidermal water loss (TEWL) and C-reactive protein (CRP) level. Rate of weight gain was higher in the SSO than the control group (adjusted mean difference, AMD = 0.90 g/kg/d, 95% confidence interval (CI) = -1.22 to 3.03 in the younger age stratum), but did not reach statistical significance. Nosocomial infection rate was significantly lower in the SSO group in the older age stratum (adjusted odds ratio (OR) = 0.41, 95% CI = 0.19 to 0.85; Topical therapy with SSO was beneficial for children with SAM when applied as adjunctive therapy. A community-based trial with a longer intervention period is recommended to validate these results. ClinicalTrials.gov: NCT02616289.

Sections du résumé

BACKGROUND BACKGROUND
Topical emollient therapy can improve neonatal health and growth and potentially provides an additional avenue for augmenting the provision of nutrition to children with severe acute malnutrition (SAM). We hypothesised that topical treatment of hospitalised children with SAM using sunflower seed oil (SSO), in addition to standard-of-care for SAM, would improve skin barrier function and weight gain, reduce risk of infection, and accelerate clinical recovery.
METHODS METHODS
We conducted a randomised, two-arm, controlled, unblinded clinical trial in 212 subjects aged 2 to 24 months who were admitted for care of SAM at the 'Dhaka Hospital' of icddr,b during January 2016 to November 2017. Enrollment was age-stratified into 2 to <6 months and 6 to 24 months age groups in a 1:2 ratio. All children received SAM standard-of-care, and the SSO group was also treated with 3 g of SSO per kg body weight three times daily for 10 days. Primary outcome was rate of weight gain over the 10-day study period. Secondary endpoints included rate of nosocomial infection, time to recovery from acute illness, skin condition score, rate of transepidermal water loss (TEWL) and C-reactive protein (CRP) level.
RESULTS RESULTS
Rate of weight gain was higher in the SSO than the control group (adjusted mean difference, AMD = 0.90 g/kg/d, 95% confidence interval (CI) = -1.22 to 3.03 in the younger age stratum), but did not reach statistical significance. Nosocomial infection rate was significantly lower in the SSO group in the older age stratum (adjusted odds ratio (OR) = 0.41, 95% CI = 0.19 to 0.85;
CONCLUSIONS CONCLUSIONS
Topical therapy with SSO was beneficial for children with SAM when applied as adjunctive therapy. A community-based trial with a longer intervention period is recommended to validate these results.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov: NCT02616289.

Identifiants

pubmed: 32509290
doi: 10.7189/jogh.10.010414
pii: jogh-10-010414
pmc: PMC7243074
doi:

Substances chimiques

Emollients 0

Banques de données

ClinicalTrials.gov
['NCT02616289']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

010414

Informations de copyright

Copyright © 2020 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form (available upon request from the corresponding author) and declare: The following authors are current or former employees and shareholders of GlaxoSmithKline: Lindsay Kendall, Xinyi Zhu, Krishan Singh, Jonathan M. Crowther, Sunita Singh, Rachel A Gibson. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Références

J Invest Dermatol. 1975 Apr;64(4):228-34
pubmed: 1117180
Acta Paediatr. 2002;91(5):546-54
pubmed: 12113324
Pediatr Infect Dis J. 1997 Aug;16(8):735-46; quiz 746-7
pubmed: 9271034
Lancet. 2013 Aug 3;382(9890):427-451
pubmed: 23746772
J Invest Dermatol. 1998 Apr;110(4):368-75
pubmed: 9540977
Pediatr Infect Dis J. 2014 Nov;33(11):1124-7
pubmed: 24853544
J Trop Pediatr. 2005 Apr;51(2):82-6
pubmed: 15677372
J Clin Invest. 1997 Aug 1;100(3):705-12
pubmed: 9239419
Indian Pediatr. 2005 Mar;42(3):255-8
pubmed: 15817974
J Health Popul Nutr. 2011 Oct;29(5):523-31
pubmed: 22106759
Dermatol Res Pract. 2012;2012:198789
pubmed: 22988452
Nutr J. 2014 Mar 20;13:22
pubmed: 24649941
J Invest Dermatol. 1975 Jun;64(6):377-85
pubmed: 167080
Pediatrics. 1993 Sep;92(3):415-9
pubmed: 8361795
Lancet. 2006 Dec 2;368(9551):1992-2000
pubmed: 17141707
J Pediatr. 1997 Feb;130(2):330-2
pubmed: 9042145
Pediatr Res. 2007 May;61(5 Pt 1):588-93
pubmed: 17413870
Glob Pediatr Health. 2016 Mar 04;3:2333794X16634267
pubmed: 27336005
Pediatr Infect Dis J. 2004 Aug;23(8):719-25
pubmed: 15295221
Pediatrics. 1976 Nov;58(5):650-4
pubmed: 824609
Acta Paediatr. 1992 Nov;81(11):859-63
pubmed: 1467605
Indian Pediatr. 1987 Dec;24(12):1111-6
pubmed: 3450663
J Trop Pediatr. 2020 Apr 1;66(2):129-135
pubmed: 31257430
J Health Popul Nutr. 2002 Jun;20(2):184-8
pubmed: 12186200
Lancet. 2005 Mar 19-25;365(9464):1039-45
pubmed: 15781099
J Trop Pediatr. 2012 Apr;58(2):88-95
pubmed: 21558307
J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):351-9
pubmed: 21336160
Bull World Health Organ. 2010 Feb;88(2):104-12
pubmed: 20428367
Food Nutr Bull. 2014 Jun;35(2):277-85
pubmed: 25076775
BMC Public Health. 2013;13 Suppl 3:S31
pubmed: 24564550
Clin Chem Lab Med. 2014 Oct;52(10):1465-72
pubmed: 24803611
Lancet. 1999 Jun 5;353(9168):1919-22
pubmed: 10371570
Pediatrics. 2008 Mar;121(3):522-9
pubmed: 18310201

Auteurs

K M Shahunja (KM)

Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Tahmeed Ahmed (T)

Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Md Iqbal Hossain (MI)

Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Mustafa Mahfuz (M)

Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh.

Lindsay Kendall (L)

GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, UK.

Xinyi Zhu (X)

GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, UK.

Krishan Singh (K)

GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, UK.

Jonathan M Crowther (JM)

JMC Scientific Consulting Ltd, Egham, Surrey, UK.

Sunita Singh (S)

GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, UK.

Rachel A Gibson (RA)

GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, Hertfordshire, UK.

Gary L Darmstadt (GL)

Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH